Category Archives: Non classé

Our mini-review entitled « In vitro models to study viral-induced asthma exacerbation: a short review for a key issue » has been published in Frontiers In Allergy !Asthma is a major health problem worldwide, which can be associated with morbidity and mortality. Respiratory viral infections are one of the most important causes of asthma exacerbation, but the underlying virus-induced mechanisms are incompletely described.To meet this urgent need and develop new efficient therapies, it is neces...

Successful collaboration with Epithelix in the characterization of AlveolAir™, a new primary 3D human alveolar model designed to advance respiratory virus research and antiviral development.The study described an innovative in vitro alveolar co-culture system at the air–liquid interface, developed by Epithelix, which maintains human primary alveolar type I and II epithelial and endothelial cells with a functional barrier for over 30 days.We characterized AlveolAir™ as a relevant system for...

Our study "Host-targeted repurposed diltiazem enhances the antiviral activity of direct acting antivirals against Influenza A virus and SARSCOV2" has been published in Antiviral Research.Influenza and SARSCoV2 infections are major public health threat with recurrent emergence and dissemination of variant strains carrying mutations resulting in suboptimal vaccine protection and/or reduced efficacy of current limited therapeutic arsenal. In this context, host-targeted approaches constitute a promi...

Virnext was pleased to attend the BioFIT Event 2024. The event provided a great opportunity to present our expertise in emerging and re-emerging respiratory viruses, as well as our continuum of in vitro and in vivo preclinical models of infection. We had valuable discussions with many professionals about how we can support their research and development projects. During the event, we highlighted our key services: Production of high-quality, characterized viruses and viral vaccine antig...

This invention relates to a proprietary recombinant metapneumovirus strain we engineered as a versatile Live-Attenuated Viral vaccine platform that can express several antigens of interest.  METAVAC® patent was exclusively licensed worldwide to Vaxxel, a spin-off from the International Research Laboratory #RESPIVIR France – Canada. Based on the METAVAC® technology, Vaxxel is developing the first intranasal bivalent vaccine candidate against human Respiratory Syncytial Virus (RSV) and hum...

Emilie Laurent, Virnext research engineer, and Aurélien Traversier, Virnext assistant engineer, have been awarded the “Cristal collectif” by the CNRS for their major contributions to the Virocrib national infrastructure (https://www.virocrib.fr/) dedicated to the screening of antiviral molecules. The collective crystal award distinguishes teams of research support staff who have carried out projects whose technical mastery, collective dimension, applications, innovation and influence are...

Building on a structured and fruitful 15-year collaboration between Manuel Rosa-Calatrava’s team at Centre International de Recherche en Infectiologie, CIRI, Lyon and Guy Boivin's laboratory at Centre de Recherche du CHU de Québec - Université Laval, Québec, Didier Samuel, chairman and CEO of INSERM and Eugénie Brouillet, Vice-Rector in charge of Research, Creation and Innovation at Université Laval, have formalised RESPIVIR (www.respivir.io) as a joint laboratory. The aim of this 5-ye...

This invention relates to a proprietary recombinant metapneumovirus strain we engineered as a versatile Live-Attenuated Viral vaccine platform that can express several antigens of interest.  METAVAC® patent was exclusive licensed worldwide to Vaxxel, a spin-off of the International Research Laboratory RESPIVIR France – Canada and Virnext. Based on the METAVAC® technology, Vaxxel is developing the first intranasal bivalent vaccine candidate against human Respiratory Syncytial Virus RSV an...

Magnificent ceremony to confer the insignia of Doctor Honoris Causa of the Université Claude Bernard Lyon 1 on Guy Boivin, Full Professor of Paediatrics at the Faculté de Médecine de l'Université Laval and Microbiologist-Infectiologist at the Centre de Recherche en Infectiologie CHU de Québe – Université Laval. Under the honorary chairmanship of Olivier Dugrip, Recteur de la région académique Auvergne-Rhône-Alpes, Recteur de l'académie de Lyon, Chancelier des universités, Gabriel...

We are thrilled to present our latest newsletter, featuring the key accomplishments and scientific breakthroughs from our Technological Research Platform and its spin-offs during the 1st half of 2024. Read the English version here: https://lnkd.in/dKbmjeWKRead the French version here: https://lnkd.in/dJfYiF3A We sincerely appreciate your support and encourage you to share this update with your network....